Big Pharma leads the list of billion-dollar deals this week with a $40 billion, unsolicited bid made by Israel’s Teva Pharmaceutical Industries Ltd. for fellow generic-drug maker Mylan N.V.
Both companies have recently been busy in the deal space. In late March, Teva turned to Goodwin Procter for counsel on its $3.2 billion buy of La Jolla, California-based orphan-drug maker Auspex Pharmaceuticals, which was advised by Cooley.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
